Newron has started pivotal development of evenamide and will soon start the line extension trial of Xadago in PD-LID. Positive results should unlock substantial equity upside. Newron is trading well below the value of Xadago with no value contributed to its pipeline targeting blockbuster sales.
Key catalysts include:
1) Start new label trial Xadago in PD-LID (Q3 2022)
2) Results “Study 014” of evenamide in TRS (Q3 2022)
3) Results “Study 008A” of evenamide in non-TRS (Q4 2022)